Blog
RSS FeedPosted by Michael Wonder on 19 Apr 2022
Supply related data in manufacturer dossiers: things are not going smoothly yet
19 April 2022 - The criteria for supply related data established by IQWiG in 2020 were positively received in science. ...
Posted by Michael Wonder on 20 Oct 2018
Is the EUnetHTA HTA core model fit for purpose? Evaluation from an industry perspective
18 October 2018 - The HTA Core Model was developed to improve the transferability of health technology assessment between settings. ...
Posted by Michael Wonder on 21 Feb 2018
Industry's experiences with the scientific advice offered by the Federal Joint Committee within the early benefit assessment of pharmaceuticals in Germany
19 February 2018 - Optional scientific advice for the early benefit assessment of pharmaceuticals is offered by the German decision maker, ...
Posted by Michael Wonder on 17 Aug 2016
German body calls for pause in European plan for fast track drug approval
16 August 2016 - Plans by the European Medicines Agency to expand its fast track approach to approving new drugs have ...
Posted by Michael Wonder on 09 Aug 2016
Adaptive pathways: EMA still leaves open questions unanswered
9 August 2016 - Current EMA report on the pilot project again documents perplexity regarding the use of “real world data”. ...
Posted by Michael Wonder on 16 Sep 2015
German drug companies are criticised for not focusing on useful therapeutic areas
15 September 2015 - A 2011 German law designed to lower prices of new innovative drugs has not been as successful ...